Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab With or Without Ipilimumab and Radiation for NSCLC Brain Metastases
NCT02696993Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2016
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2016; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02696993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02696993.